Introduction
============

Diabetic retinopathy (DR), one of the most prominent pathological microvascular complications of type 2 diabetes, is the leading cause of blindness among people of working age in developed countries[@b1],[@b2]. The prevalence of DR in diabetics is approximately 37% in China[@b3], where DR currently places a large public health and economic burden on the country.

Adiponectin has been shown to play a protective role in preventing macrovascular disorders, and has gained considerable attention because of its involvement in cardiovascular disease[@b4]; however, the role of adiponectin in the development of DR is largely unknown. Endothelial dysfunction pathways are thought to play an important role in the pathogenesis of DR[@b5], and *in vitro* data have shown that adiponectin is an adipocyte-specific secretory protein that modulates endothelial cell functions[@b6],[@b7], endothelial cell dysfunction is thought to play a major role in the development of diabetic microangiopathy. As adiponectin is involved in the modulation of angiogenesis, it could be a new candidate gene involved in promoting the progression of DR.

Nowadays, the examination of gene--environment interactions is increasingly popular. Although the traditional logistic regression model is often used to detect interactions, it is difficult to evaluate potential higher-order interactions when dealing with greater dimensional data; however, the multifactor dimensionality reduction (MDR) method makes this possible, which is very powerful to detect high-order gene--environment interactions in studies with relatively small sample sizes[@b8], and to detect interactions without main effects[@b9].

A susceptibility locus for metabolic syndrome and diabetes was previously mapped to human chromosome 3q27[@b10], where the adiponectin gene is located[@b11],[@b12]. As little is known about the possible role of the adiponectin gene and its interaction with environmental factors on DR risk, we chose to genotype C-11377G (rs266729; 5′ flanking region), A-4034C (rs822394; intron 1) to tag block 1, and G276T (rs1501299; intron 2) and T45G (rs2241766; exon 2) to tag block 2, because these are the four most common polymorphisms and are able to tag all common haplotypes at the adiponectin locus. These common haplotypes (frequency \>5%) account for more than 70% of the haplotypes at this locus[@b13]. Furthermore, these four polymorphisms have been extensively studied regarding their functionality and relationship with diabetes[@b11]--[@b13].

The polymorphisms of C-11377G (rs266729), G276T (rs1501299) and T45G (rs2241766) have been proved to be associated with type 2 diabetes[@b14]--[@b16]. Our previous study involving 36,974 cases and 68,838 controls also showed that C-11377G (rs266729) might be associated with type 2 diabetes risk[@b17].

The adiponectin gene has been shown to be related to serum adiponectin levels among various ethnicities[@b18]--[@b20]. In epidemiological studies, serum levels of adiponectin predicted the risk of type 2 diabetes[@b21]--[@b23], evidence suggests that the genetic variations in adiponectin gene might affect the serum adiponectin levels and cause insulin resistance.

Both G alleles of T45G (rs2241766) and G276T (rs1501299) are associated with the lower serum adiponectin levels in type 2 diabetes patients[@b15],[@b24],[@b25]. Thus, the adiponectin gene gains much more importance in its relationship with diabetes and serum adiponectin levels. However, the role of adiponectin in the pathogenesis of DR is still largely unknown. Relevant clinical studies have been inconclusive[@b26]--[@b28]. Therefore, we investigated the possible role of serum adiponectin levels and adiponectin gene polymorphisms in the development of DR, and we attempted to detect whether the gene--environment interaction modifies DR risk.

Materials and Methods
=====================

Study Population
----------------

This was a population-based cross-sectional study. Chinese patients with type 2 diabetes were consecutively recruited between January 2011 and December 2011 from the Wenhua community clinics of Qiqihar City, China. Considering the possible influence of duration of diabetes, non-DR patients with shorter diabetes duration might develop DR later on, we excluded all the non-DR patients with duration of diabetes \<10 years, therefore the present study involved 372 diabetic patients with DR and 145 patients with diabetes, but without DR. All participants provided written informed consent. The study protocol complies with the Declaration of Helsinki, and was approved by the Committees on the Ethics of Human Research of Harbin Medical University, Harbin, China.

All participants underwent fundus fluorescein angiography carried out by ophthalmologists. They were classified as diabetic with retinopathy or diabetic without retinopathy according to standard diagnostic criteria[@b29]. The following were excluded: (i) patients with diabetes undergoing thiazolidinedione therapy; (ii) patients with diagnosed diabetic nephropathy or neuropathy; (iii) patients with acute or chronic inflammatory disease; and (iv) patients with type 1 diabetes, maturity-onset diabetes of the young or mitochondrial diabetes.

Data Collection
---------------

Smoking was defined as never, past or current. Questions about smoking included the average number of cigarettes smoked per day and pack-years of smoking (\<20, 20--30, 30--40 and ≥40 pack-years).

We calculated alcohol intake (g/day) for each individual based on the type and amount of alcoholic beverages consumed. According to the Chinese Food Composition Table 2004, 50 mL of hard liquor was defined as 21.85 g, 50 mL of light liquor as 15.75 g, one 640-mL bottle of beer as 31.36 g and 50 mL of wine as 5.20 g[@b30]. The reported daily intake of alcohol was classified into one of five groups: no intake (0 g/day), little intake (\<13 g/day), moderate intake (13--26 g/day), heavy intake (26--88 g/day) and very heavy intake (≥88 g/day).

Participants reported physical activity (type, h/week and years of participation in each activity) as the average time engaged in specific activities during the previous year. Physical activity energy expenditure was estimated using standard metabolic equivalent values (MET)[@b31]. Four levels of physical activity were defined: no exercise, light-intensity physical activity, moderate-intensity physical activity and vigorous-intensity physical activity.

Other factors included in the present study were: age (continuous), sex (male/female), average family income per month (\<1000, 1000--2999, 2999--5999, ≥6000 CNY), marital status (single, married, widowed, divorced), level of education (less than primary and primary, junior and senior middle, junior college, college and above), insulin therapy administration (yes or no), pressure from family income (yes or no), family stress (yes or no), family history of diabetes (yes or no) and family history of hypertension (yes or no).

Diagnostic Criteria
-------------------

Diagnosis and classification of diabetes was based on clinical features, laboratory data and the guidelines in the recent Expert Committee Report of the American Diabetes Association[@b32]. The glycated hemoglobin values were converted based on the equation of two articles[@b33],[@b34].

Biochemical Measurements
------------------------

Cases and controls were mixed for genotyping, and laboratory personnel were unaware of the case or control status. To ensure quality control and evaluate the intrasubject concordance rate, 50 duplicate samples were randomly genotyped twice. Concordance rates for all assays were \>99%. Genotyping of each participant was finished by a MassARRAY compact analyzer (Sequenom, San Diego, CA, USA). The oligonucleotide sequences used for genotyping were shown in Table[1](#tbl1){ref-type="table"}.

###### 

Oligonucleotide sequence used for genotyping

  SNP                Primer                                 Sequence
  ------------------ -------------------------------------- --------------------------------------
  C-11377G           1st PCR                                5′-ACGTTGGATGATGTGTGGCTTGCAAGAACC-3′
  2nd PCR            5′-ACGTTGGATGTTGGACTTTCTTGGCACGCT-3′   
  Extension primer   5′-ACGCTCATGTTTTGTTTTTGAAG-3′          
  A-4034C            1st PCR                                5′-ACGTTGGATGATCAGAGTCCGTTCTTGGTC-3′
  2nd PCR            5′-ACGTTGGATGGGTAGAGGTGCCAAAAATAC-3′   
  Extension primer   5′-GTGCCAAAAATACAAGAGTG-3′             
  T45G               1st PCR                                5′-ACGTTGGATGAGGGCTCAGGATGCTGTTG-3′
  2nd PCR            5′-ACGTTGGATGCCTTGAGTCGTGGTTTCCTG-3′   
  Extension primer   5′-TTGAGTCGTGGTTTCCTGGTCATG-3′         
  G276T              1st PCR                                5′-ACGTTGGATGCTTTCTCCCTGTGTCTAGGC-3′
  2nd PCR            5′-ACGTTGGATGCTCTTTCATCACAGACCTCC-3′   
  Extension primer   5′-CCTACACTGATATAAACTATATGAAG-3′       

PCR, polymerase chain reaction; SNP, single-nucleotide polymerase chain reaction.

The process was as follows: (i) deoxyribonucleic acid isolation; (ii) primer design; (iii) polymerase chain reaction; (iv) neutralization of unincorporated deoxyribonucleoside triphosphates (shrimp alkaline phosphatase reaction); (v) extend reaction; (vi) conditioning of iPLEX Gold reaction products (Sequenom Co., Ltd., San Diego, CA, USA); (vii) application to the SpectroCHIP II array (Sequenom Co., Ltd.); (viii) definition of assays and plates; and (ix) spectrum acquisition and analysis.

Human adiponectin serum levels were measured by enzyme-linked immunosorbent assay according to the protocol provided by the manufacturer (human adiponectin ELISA kit; R&D Systems, Abingdon, UK. Standard range: 0.156--10 ng/mL; sensitivity: 0.1 ng/mL; intra-assay precision: \<5--10%; interassay precision: \<15%; specificity: this assay recognizes recombinant and natural human sdiponectin/Acrp30).

Statistical Analysis
--------------------

Group differences were analyzed by Student\'s *t*-test, the Mann--Whitney *U*-test and the χ^2^-test. Calculations of genotype frequency and Hardy--Weinberg equilibrium (HWE) were carried out using SNPStats online tools (<http://bioinfo.iconcologia.net/snpstats/start.htm>). Using codominant, dominant and recessive genetic models, the associations between the selected single-nucleotide polymorphisms (SNPs) and DR susceptibility were analyzed. The linkage disequilibrium (LD) between the adiponectin polymorphisms was assessed with the Haploview software package version 4.2 (<http://bioinfo.iconcologia.net/snpstats/start.htm>).

We carried out three independent tests of the four polymorphisms. To avoid spurious associations with false positive outcomes, Bonferroni\'s method was applied to the significance thresholds[@b35], and a *P*-value \<0.004 was used as the significant threshold across the four polymorphisms for each genetic model. Odds ratios (ORs) and 95% confidence intervals (CIs) of the environmental factors were estimated using an unconditional logistical regression model. Univariate logistic regression analyses examined the independent impact of each risk factor on DR susceptibility, and then a multivariable logistic regression analysis was carried out.

Gene--environment interactions were evaluated by MDR software (version 2.0 beta) (<http://www.epistasis.org>). Multilocus genotype and discrete environmental factors were pooled into high- and low-risk groups to reduce the multifactor prediction from *n* dimensions to one dimension. MDR uses cross-validation by dividing the data into a training set (e.g., 9/10 of the data) and a testing set (e.g., the remaining 1/10 of the data) to derive estimates of cross-validation consistency (CVC) and testing accuracy. CVC is defined as the number of times a particular interaction model is selected across 10 cross-validation datasets, with the corresponding *P*-value. Accuracy is a function of the percentage of true positives (TP), true negatives (TN), false positives (FP) and false negatives (FN), and is defined as (TP + TN) / (TP + TN + FP + FN)[@b36]. MDR minimizes false-positive results that might otherwise result from multiple examinations of the data[@b37]. A final model is then chosen based on maximization of CVC and highest testing balance accuracy. These MDR permutation results were considered statistically significant at the 0.05 level.

As MDR itself cannot show the main effects of interaction between risk factors, we also applied traditional multiple regression models to further explain the results of the MDR analysis and provide meaningful epidemiological interpretations. The power estimation between the SNPs and DR was calculated using the software Power/sample size analysis, while power estimation between the SNPs and plasma adiponectin levels was calculated with Power And Precision (<http://www.power-analysis.com/>).

Results
=======

Basic Characteristics
---------------------

Sociodemographic characteristics between 372 cases and 145 controls were similar (Table[2](#tbl2){ref-type="table"}), but there were significant differences in low-density lipoprotein cholesterol, fasting blood glucose and 2-h plasma glucose.

###### 

Demographic information and socioeconomic status of cases and controls

                                       Cases              Controls           *P*-value
  ------------------------------------ ------------------ ------------------ --------------------------------------
  *n*                                  372                145                
  Age (mean ± SD)                      63.39 ± 10.60      62.34 ± 10.75      0.31
  Sex (male/female)                    146/226            49/96              0.25
  Education level                                                            0.95
   Less than primary and primary (%)   209 (56%)          84 (57.9%)         
   Junior and senior middle (%)        110 (29.5%)        42 (28.9%)         
   Junior college (%)                  36 (9.8%)          12 (8.2%)          
   College and above (%)               17 (4.7%)          7 (5%)             
  Income group ¥                                                             0.73
   \<1000 (%)                          85 (22.8%)         38 (26.2%)         
   1000--2999 (%)                      242 (65.1%)        92 (63.4%)         
   2999--5999 (%)                      39 (10.4%)         14 (9.7%)          
  ≥6000 (%)                            6 (1.7%)           1 (0.7%)           
  Marital status                                                             0.84
   Single (%)                          6 (1.6%)           1 (0.7%)           
   Married (%)                         322 (86.6%)        125 (86.2%)        
   Widowed (%)                         2 (0.6%)           1 (0.7%)           
   Divorce (%)                         42 (11.2%)         18 (12.4%)         
  BMI (kg/m^2^)                        24.48 ± 3.45       24.22 ± 3.36       0.43
  WHR                                  0.92 ± 0.14        0.91 ± 0.09        0.42
  SBP (mmHg)                           133.85 ± 16.48     133.18 ± 15.78     0.67
  DBP (mmHg)                           80.62 ± 10.46      79.97 ± 9.53       0.51
  TC (mmol/L)                          5.49 ± 1.02        5.45 ± 1.01        0.68
  TG (mmol/L)                          2.21 ± 1.27        2.17 ± 1.13        0.74
  HDL-C (mmol/L)                       1.30 ± 0.31        1.31 ± 0.32        0.74
  LDL-C (mmol/L)                       2.81 ± 0.46        2.90 ± 0.44        0.04[](#tf2-1){ref-type="table-fn"}
  FBG (%)                              8.47 ± 3.43        7.58 ± 3.68        0.009[](#tf2-1){ref-type="table-fn"}
  2hPG (%)                             13.01 ± 4.36       11.98 ± 4.22       0.01[](#tf2-1){ref-type="table-fn"}
  HbA1~C~,% (mmol/mol)                 9.43 (80) ± 2.33   8.98 (71) ± 2.55   0.055
  Duration of diabetes                 14.27 ± 4.21       14.46 ± 5.01       0.66

Significant results. Numbers are given as *n* (%). 2hPG, 2-h plasma glucose; BMI, body mass index; DBP, diastolic blood pressure; FBG, fasting blood glucose; HbA1~c~, glycated hemoglobin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; SD, standard deviation; TC, total cholesterol; TG, triglyceride; WHR, waist-to-hip ratio.

Power Calculation
-----------------

Power was estimated using the number of case patients, the ratio of control-to-case patients, the type 1 error probability for a two-sided test, the prevalence of the putative susceptibility allele in the control population and the unadjusted odds ratio of exposure in cases relative to controls. The number of case patients in the present study was (372 × 2) = 744, the ratio of control-to-case patients was 0.38, and the minor allele frequency of G276T (rs1501299) and T45G (rs2241766) was 29 and 30%, respectively[@b38], a genotype relative risk of 1.2 or 1.5, a type 1 error rate of 0.05 and the statistical power \>80% was attained if the allele risk was equal to 1.5. However, if allele risk was 1.2, its power was lower than 80% to evaluate the association.

To detect a true association between the SNPs and plasma adiponectin levels, the study had 93, 68, 82 and 73% power to detect the association of C-11377G (rs266729), A-4034C (rs822394), G276T (rs1501299), and T45G (rs2241766) variants with plasma adiponectin levels, respectively.

Distribution of C-11377G, A-4034C, T45G and G276T Adiponectin Gene Polymorphism, Linkage Disequilibriums and Haplotypes
-----------------------------------------------------------------------------------------------------------------------

The genotype distributions among controls were in accordance with HWE (data not shown). Genotype analysis for the four adiponectin gene polymorphisms yielded no significant association with DR after the Bonferroni method. However, it is possible that the stringent corrective nature of the Bonferroni method might result in decreased power (Table[3](#tbl3){ref-type="table"}). A significant LD was observed between rs1501299 and rs2241766 polymorphisms (D\' = 1, *r*^2^ = 0.142), but haplotype analysis did not provide a significant result (data not shown).

###### 

Genotype and allele distribution of adiponectin gene polymorphisms in type 2 diabetes with and without retinopathy

  Model                            Genotype     Cases (%)    Control (%)          OR (95% CI)       *P*-value
  -------------------------------- ------------ ------------ -------------------- ----------------- -----------
  C-11377G (rs266729) *n* = 1039                                                                    
   Codominant                      C/C          190 (51.1)   67 (46.2)            1.00 (Referent)   --
  C/G                              148 (39.8)   60 (41.4)    1.15 (0.76--1.73)    0.43              
  G/G                              34 (9.1)     18 (12.4)    1.30 (0.68--2.49)                      
   Dominant                        C/C          190 (51.1)   67 (46.2)            1.00 (Referent)   
  C/G-G/G                          182 (48.9)   78 (53.8)    1.21 (0.82--1.78)    0.37              
   Recessive                       C/C-C/G      338 (90.9)   127 (87.6)           1.00 (Referent)   
  G/G                              34 (9.1)     18 (12.4)    1.40 (0.76--2.58)    0.34              
  A-4034C (rs822394) *n* = 1040                                                                     
   Codominant                      C/C          288 (77.4)   112 (77.2)           1.00 (Referent)   --
  A/C                              80 (21.5)    31 (21.4)    0.99 (0.62--1.59)    0.95              
  A/A                              4 (1.1)      2 (1.4)      1.29 (0.22--7.40)                      
   Dominant                        C/C          288 (77.4)   112 (77.2)           1.00 (Referent)   --
  A/C-A/A                          84 (22.6)    33 (22.8)    1.01 (0.63--1.59)    0.96              
   Recessive                       C/C-A/C      368 (98.9)   143 (98.6)           1.00 (Referent)   --
  A/A                              4 (1.1)      2 (1.4)      1.28 (0.23--7.10)    0.77              
  T45G (rs2241766) *n* = 1035                                                                       
   Codominant                      T/T          206 (55.5)   82 (56.6)            1.00 (Referent)   --
  T/G                              140 (37.7)   53 (36.6)    0.95 (0.63--1.42)    0.96              
  G/G                              25 (6.7)     10 (6.8)     1.05 (0.47--2.34)                      
   Dominant                        T/T          206 (55.5)   82 (56.6)            1.00 (Referent)   --
  T/G-G/G                          165 (44.5)   63 (43.4)    0.95 (0.65--1.41)    0.91              
   Recessive                       T/T-T/G      346 (93.3)   135 (93.2)           1.00 (Referent)   --
  G/G                              25 (6.7)     10 (6.8)     1.02 (0.48--2.19)    0.94              
  G276T (rs1501299) *n* = 1040                                                                      
   Codominant                      G/G          164 (44.1)   82 (56.5)            1.00 (Referent)   --
  G/T                              169 (45.4)   55 (38)      0.65 (0.43--0.97)    0.02              
  T/T                              39 (10.5)    8 (5.5)      0.63 (0.27--1.43)                      
   Dominant                        G/G          164 (44.1)   82 (56.5)            1.00 (Referent)   --
  G/T-T/T                          208 (55.9)   63 (43.5)    0.60 (0.41--0. 89)   0.01              
   Recessive                       G/G-G/T      333 (89.5)   137 (94.5)           1.00 (Referent)   --
  T/T                              39 (10.5)    8 (5.5)      0.49 (0.22--1.09)    0.11              

Genotype distributions are shown as *n* (%). Odds ratios (OR), 95% confidence intervals (CI), and *P*-values were from logistic regression analyses with codominant, dominant, recessive model controlling for family history of diabetes, insulin therapy and physical activity.

Univariate and Multivariable Logistic Regression Analysis
---------------------------------------------------------

In univariate analysis, we found that insulin therapy (2.16, 1.45--3.22), family history of diabetes (2.14, 1.38--3.31), history of hypertension (1.83, 1.24--2.71) and family stress (2.22, 1.02--4.82) contributed to an increased risk of DR, whereas moderate physical activity (0.41, 0.20--0.83) played a protective role in the development of DR after adjusting for low-density lipoprotein cholesterol, fasting plasma glucose and 2-h plasma glucose (Table[4](#tbl4){ref-type="table"}).

###### 

Main effects of environment-related factors on diabetic retinopathy by univariate logistic regression

                                             Cases (%)    Controls (%)   OR (95% CI)          *P*-value
  ------------------------------------------ ------------ -------------- -------------------- ---------------------------------------
  Smoking status                                                                              
   Never                                     301 (80.8)   120 (82.6)     1.000 (Referent)     --
   Past                                      23 (6.2)     6 (4.2)        0.65 (0.26--1.64)    0.48
   Current                                   48 (13.0)    19 (13.2)      1.51 (0.53--4.30)    0.59
  Daily amount of smoking (Cigarettes/day)                                                    
   \<5                                       37 (10.0)    21 (14.5)      1.000 (Referent)     --
   5--9                                      89 (24.0)    34 (23.5)      0.67 (0.34--1.30)    0.31
   10--19                                    111 (30.0)   46 (31.7)      1.08 (0.64--1.83)    0.86
   ≥20                                       134 (36.0)   44 (30.3)      0.79 (0.48--1.28)    0.41
  Pack years of smoking                                                                       
   \<20                                      133 (35.6)   52 (35.7)      1.000 (Referent)     --
   20--30                                    122 (32.8)   42 (29)        0.88 (0.54--1.41)    0.68
   30--40                                    82 (22.1)    28 (19.3)      0.99 (0.57--1.72)    0.97
   ≥40                                       35 (9.5)     23 (16)        1.92 (0.97--3.79)    0.08
  Ethanol intake (g/day)                                                                      
   No intake                                 346 (93.0)   136 (93.8)     1.000 (Referent)     --
   \<13 (g/day)                              8 (2.2)      2 (1.4)        0.63 (0.13--3.03)    0.82
   13--26 (g/day)                            6 (1.6)      2 (1.4)        1.33 (0.14--12.36)   0.80
   26--88 (g/day)                            6 (1.6)      3 (2)          1.50 (0.18--12.45)   0.70
   ≥88 (g/day)                               6 (1.6)      2 (1.4)        0.66 (0.08--5.53)    0.70
  Physical activity                                                                           
   No exercise                               107 (28.8)   58 (40)        1.000 (Referent)     --
   Light-intensity                           193 (51.9)   75 (51.7)      0.71 (0.47--1.08)    0.14
   Moderate-intensity                        68 (18.3)    11 (7.6)       0.41 (0.20--0.83)    0.01[](#tf4-1){ref-type="table-fn"}
   Vigorous-intensity                        4 (1.0)      1 (0.7)        1.54 (0.15--15.14)   0.70
  Insulin therapy                                                                             
   No                                        198 (53.2)   50 (34.5)      1.000 (Referent)     
   Yes                                       174 (46.8)   95 (65.5)      2.16 (1.45--3.22)    0.0001[](#tf4-1){ref-type="table-fn"}
  Family history of diabetes                                                                  
   No                                        304 (81.7)   98 (67.6)      1.000 (Referent)     --
   Yes                                       68 (18.3)    47 (32.4)      2.14 (1.38--3.31)    0.001[](#tf4-1){ref-type="table-fn"}
  History of hypertension                                                                     
   No                                        249 (67)     86 (59.3)      1.000 (Referent)     --
   Yes                                       123 (33)     59 (40.7)      1.83 (1.24--2.71)    0.003[](#tf4-1){ref-type="table-fn"}
  Income pressure                                                                             
   Never                                     284 (76.3)   111 (76.6)     1.000 (Referent)     --
   Occasional                                62 (16.7)    26 (17.9)      1.07 (0.64--1.78)    0.88
   Daily                                     26 (7.0)     8 (5.5)        0.73 (0.29--1.83)    0.66
  Family stress                                                                               
   Never                                     264 (71)     109 (75.2)     1.000 (Referent)     --
   Occasional                                77 (20.7)    19 (13.1)      0.59 (0.34--1.03)    0.08
   Daily                                     31 (8.3)     17 (11.7)      2.22 (1.02--4.82)    0.04[](#tf4-1){ref-type="table-fn"}
  BMI (kg/m^2^)                                                                               
   \<24 (%)                                  169 (45.3)   62 (42.8)      1.000 (Referent)     --
   24--28 (%)                                152 (40.9)   62 (42.8)      1.11 (0.73--1.68)    0.69
   \>28 kg/m^2^ (%)                          51 (13.8)    21 (14.4)      1.01 (0.56--1.81)    0.97

Significant results in univariate logistic regression after adjusting for low-density lipoprotein cholesterol, fasting plasma glucose and 2-h plasma glucose.

Our multivariable logistic regression analysis results showed that the family history of diabetes and insulin therapy were identified as high risk factors for DR, whereas physical activity appeared to play a protective role in the development of DR (Table[5](#tbl5){ref-type="table"}).

###### 

Multivariate logistic regression analysis of environment factors

                               β        SE     Wald χ^2^   OR (95% CI)         *P*-value
  ---------------------------- -------- ------ ----------- ------------------- --------------------------------------
  Physical activity                                                            
   No exercise                                             1.000 (Referent)    --
   Light-intensity             0.26     0.15   1.11        1.28 (0.72--1.81)   0.25
   Moderate-intensity          --0.37   0.11   6.05        0.57 (0.37--0.89)   0.01[](#tf5-1){ref-type="table-fn"}
   Vigorous-intensity          0.07     0.12   0.25        1.42 (0.41--3.56)   0.98
  Insulin therapy                                                              
   No                                                      1.000 (Referent)    --
   Yes                         0.62     0.15   16.01       1.78 (1.38--2.36)   0.001[](#tf5-1){ref-type="table-fn"}
  Family history of diabetes                                                   
   No                                                      1.000 (referent)    --
   Yes                         1.12     0.18   25.8        1.75 (1.43--2.69)   0.001[](#tf5-1){ref-type="table-fn"}

Significant results in multivariable logistic regression. CI, confidence interval; OR, odds ratio.

Interestingly, when we controlled for the family history of diabetes and physical activity in the multivariable logistic regression analysis, the corresponding OR and 95% CI for insulin therapy with DR was 1.67 (1.21--2.32).

Association of Adiponectin Gene Polymorphisms With Serum Adiponectin Levels
---------------------------------------------------------------------------

To assess whether genetic variation of adiponectin gene polymorphisms influenced serum adiponectin levels, we had carried out the analysis with one-way analysis of variance. However, no significant association was found between the adiponectin gene polymorphisms and serum adiponectin levels (Table[6](#tbl6){ref-type="table"}). Besides, the associations between adiponectin serum levels and adiponectin SNPs were also evaluated by linear regression analysis adjusted for age, sex and BMI; however, we did not find any significant associations between adiponectin serum levels and four adiponectin SNPs (*P* \> 0.05).

###### 

Comparison of serum adiponectin levels of different genotypes

  SNPs                    1/1[a](#tf6-1){ref-type="table-fn"}   1/2[b](#tf6-1){ref-type="table-fn"}   2/2[c](#tf6-1){ref-type="table-fn"}   *P*
  ----------------------- ------------------------------------- ------------------------------------- ------------------------------------- ------
  −11377C\>G (rs266729)   7.95 ± 5.42                           7.97 ± 5.61                           7.73 ± 6.27                           0.94
  A-4034C (rs822394)      8.66 ± 4.91                           7.96 ± 5.01                           7.91 ± 5.75                           0.90
  +45T\>G (rs2241766)     7.98 ± 7.95                           8.37 ± 5.16                           7.69 ± 5.46                           0.35
  +276G\>T (rs1501299)    7.79 ± 5.77                           7.84 ± 5.25                           8.03 ± 5.84                           0.89

Wild-type homozygote/^b^heterozygote/^c^variant homozygote. SNPs, single-nucleotide polymorphisms.

Relationship Between Serum Adiponectin Levels and Diabetic Retinopathy
----------------------------------------------------------------------

We did not find significant differences in the serum adiponectin levels between the cases and controls (8.97 ± 7.59 vs 8.68 ± 6.33 μg/mL, *P* = 0.68). The association of serum adiponectin and diabetic retinopathy had been evaluated by unconditional logistic regression analysis with the adjustment for age, sex, BMI and diabetes duration, and the results showed that serum adiponectin was not associated with DR (data not shown).

Loci--Loci, Environment--Environment and Gene--Environment Interactions Using MDR and Traditional Multiple Regression Models
----------------------------------------------------------------------------------------------------------------------------

The analysis was run separately for loci--loci (adiponectin polymorphisms), environment--environment (all environmental factors) and gene--environment datasets (adiponectin polymorphisms and all environmental factors). For the loci--loci dataset, there was no significant interaction based on MDR analysis or from traditional multiple regression models (Table[7](#tbl7){ref-type="table"}).

###### 

Summary of results for diabetic retinopathy risk prediction from multifactor dimensionality reduction analysis

  Model                                                                            Training balance accuracy   Testing balance accuracy   Cross validation consistency   OR (95% CI)         *P*-value permutation test
  -------------------------------------------------------------------------------- --------------------------- -------------------------- ------------------------------ ------------------- ----------------------------
  Loci--loci interaction model                                                                                                                                                               
   +276G\>T                                                                        0.58                        0.56                       10/10                          0.82 (0.61--1.08)   0.12
   --11377C\>G, +276G\>T                                                           0.55                        0.51                       6/10                           0.95 (0.39--2.12)   0.89
   −11377C\>G, A -4034C, +276G\>T                                                  0.56                        0.53                       9/10                           1.70 (0.74--3.67)   0.17
   --11377C\>G, A -4034C, +45T\>G, +276G\>T                                        0.57                        0.49                       10/10                          0.96 (0.39--2.12)   0.92
  Environment--environment interaction model                                                                                                                                                 
   Family history of diabetes                                                      0.63                        0.64                       10/10                          2.82 (2.29--3.53    0.001
   Family history of diabetes, insulin therapy                                     0.65                        0.68                       10/10                          3.29 (2.34--4.26)   0.001
   Duration of diabetes, family history of diabetes, insulin therapy               0.65                        0.65                       8/10                           2.89 (2.12--4.52)   0.001
  Gene--environment interaction model                                                                                                                                                        
   Insulin therapy                                                                 0.63                        0.63                       10/10                          2.01 (1.71--3.12)   0.0001
   C-11377G (rs266729), insulin therapy                                            0.64                        0.65                       10/10                          2.53 (1.91--3.31)   \<0.0001
   Family stress, history of hypertension, insulin therapy                         0.65                        0.62                       7/10                           1.95 (0.85--4.43)   0.1
   G276T (rs1501299), family stress, family history of diabetes, insulin therapy   0.67                        0.62                       6/10                           2.13 (1.05--5.12)   0.05

The best model is the one with the maximum cross-validation consistency and maximum testing balance accuracy. CI, confidence interval; OR, odds ratio.

For the environment--environment dataset, the two-factor model consisting of the family history of diabetes and insulin therapy with a testing balance accuracy of 0.68 and a CVC of 10/10 was the best model identified (95% CI, 2.34--4.26; *P* = 0.001). For the gene--environment dataset, the two-factor interaction model of --11377C\>G and insulin therapy was the best model identified with a maximum CVC of 10/10 and a highest testing balance accuracy of 65%, this was statistically significant as determined by 1,000-fold permutation testing (95% CI 1.91--3.31, *P* \< 0.0001; Table[7](#tbl7){ref-type="table"}).

To further explain the epidemiological implications of the best interaction models identified by MDR analysis, traditional multiple regression models was used to further test the interaction, and the results confirmed the interaction between family history of diabetes and insulin therapy (OR 1.36, 95% CI 1.11--1.87, *P* = 0.001), C-11377G (rs266729) and insulin therapy (OR 1.65, 95% CI, 1.13--2.52, *P* \< 0.0001) after adjusting for corresponding confounding factors.

Figure[1](#fig01){ref-type="fig"} shows and classifies the different interaction items into high and low risk. Patients receiving insulin therapy and who had the C-11377 G (rs266729) GG genotype were susceptible to DR (Figure[1](#fig01){ref-type="fig"}a). Furthermore, patients with insulin therapy and with a family history of diabetes were prone to DR (Figure[1](#fig01){ref-type="fig"}b).

![(a) The identified best model in gene--environment interaction. Distribution of high-risk (dark shading) and low-risk (light shading) combinations associated with diabetic retinopathy (DR) in a gene--environment model. High-risk factors are in the dark gray and low-risk factors are in the light gray. The number of DR patients (left bar in boxes) and control subjects (right bar in boxes) are shown for each square array. A1: insulin therapy, 0 for not taking insulin therapy, 1 for taking insulin therapy; A2: C-11377G (rs266729), 0 for CC genotype, 1 for CG genotype and 2 for GG genotype. (b) The identified best model in environment--environment interaction. High-risk factors are in the dark gray and low-risk factors are in the light gray. The number of DR patients (left bar in boxes) and control subjects (right bar in boxes) are shown for each square array. B1: insulin therapy, 0 for not taking insulin therapy, 1 for taking insulin therapy; B2: family history of diabetes, 0 for not with family history of diabetes, 1 for with family history of diabetes.](jdi0006-0056-f1){#fig01}

Discussion
==========

Using both the MDR and traditional multiple regression models, the present study showed the consistent result of a gene--environmental interaction between C-11377 G (rs266729) and insulin therapy on the risk of DR. Multivariable logistic regression analysis identified that insulin therapy increased the susceptibility to DR (OR 1.78, 95% CI 1.38--2.36), but that the interaction between C-11377 G (rs266729) and insulin therapy further enhanced its risk (OR 2.53, 95% CI 1.91--3.31). This suggests that patients carrying the GG genotype of C-11377 G (rs266729) and taking insulin therapy are more likely to develop DR. The present findings therefore highlight the potential gene--environmental role in the progression of DR. However because of the cross-sectional study design, the present findings might be overstated and need to be confirmed in future prospective studies.

Currently, one study has investigated the effect of adiponectin gene polymorphism G276T (rs1501299) on DR susceptibility in the Japanese population[@b39]; however, their sample sizes were small, and no significant associations were observed. Besides, Eun Yeong Choe *et al*.[@b38] examined the association between rs2241766 and rs1501299 in adiponectin with diabetic microvascular complications in 708 Korea, patients with type 2 diabetes, but also found negative associations with DR. Although the statistical significance between G276T (rs1501299) and DR susceptibility was not suggested in the present study, we additionally included two more of the most common adiponectin SNPs and environmental factors, but no significant associations were found between any of the four adiponectin gene polymorphisms and DR susceptibility, showing that the SNPs of the adiponectin gene alone might not be associated with DR risk in the Chinese population, but its C-11377 G (rs266729) might interact with insulin therapy to increase the risk of DR. Besides, the SNPs of the present study also had no influence on the serum adiponectin levels, this is might be due to the linkage disequilibrium structures in the present study that do not result in a change in serum adiponectin levels. A study reported by Zietz *et al*.[@b40] also suggested that T45G (rs2241766) didn\'t influence the adiponectin serum levels and elevated adiponectin serum levels were associated with DR in patients with type 2 diabetes.

The overall best model by MDR in the present study was the interaction between C-11377G (rs266729) and insulin therapy, which might be associated with the increased risk of DR. The significance of this interaction was further confirmed by traditional multiple regression models. Our previous study identified an association between the G vs C allele of C-11377 G (rs266729) and type 2 diabetes[@b17]. Together, the present study also showed that C-11377 G (rs266729) might be a potential risk factor involved in the development of diabetes that could also mediate the effects of insulin therapy on DR risk.

Insulin is the mainstay of treatment for type 2 diabetes, but insulin therapy was found to be a risk factor for DR in our multivariable analysis. This is consistent with the Beijing Eye study, which found that insulin therapy increases the risk of DR by 5.6-fold[@b3]. Furthermore, a population-based study in southern Wisconsin showed that worsening of retinopathy occurred in 41% of insulin-taking diabetics, whereas just 7% of insulin-taking diabetics showed improvement in retinopathy[@b41]. Interestingly, the present study showed that even after controlling for the duration of diabetes and physical activity in multivariable logistic regression analysis, insulin therapy alone was still associated with the risk of DR.

Serum adiponectin levels did not differ between the DR group and non-DR group in the present study. Zietz *et al*.[@b40] reported higher plasma adiponectin concentrations in DR and Kato *et al*.[@b28] showed that adiponectin levels were positively correlated with the severity of DR, this observation might as a result of the decompensated increase of adiponectin in repairing endothelial function damage, because adiponectin has novel vascular actions to directly stimulate production of nitric oxide in endothelial cells[@b42]. Yilmaz[@b26] showed that adiponectin levels were lower in patients with DR, whereas Hotta *et al*.[@b43] suggested that plasma levels of adiponectin did not differ between diabetic patients with and without retinopathy. The differences among the aforementioned studies might be because adiponectin levels are influenced by various factors, such as degree of obesity, pharmacological therapy with thiazolidinediones and so on[@b44].

The present study had a number of limitations. The first limitation was the retrospective study design -- a large-scale prospective study is required to confirm our findings. Second, because of the small number of proliferative retinopathy (PDR) patients, we did not further classify DR patients into non-PDR and PDR groups. As a result of the relatively small sample size of the study, the power was not enough to detect a true association between SNPs and disease (OR 1.2), but comprehensive analytical methods might help us to indentify the potential gene--environment associations efficiently.

Despite these limitations, the strengths of the present study include the availability of questionnaire data to quantify personal and environmental exposure, the rigorous genotyping and the availability of treatment history from patient medical records. Furthermore, gene--environment interactions were consistently identified by both parametric and non-parametric statistical models to explore the main effects and potential interactions. The results identified by MDR were further confirmed by traditional multiple regression models when controlling for confounding variables simultaneously.

These findings suggest that clinicians should be careful in recommending insulin therapy to patients with family history of diabetes combined with the C-11377 G (rs266729) GG genotype. Future studies should explore the possible role and mechanism of the adiponectin C-11377 G (rs266729) polymorphism in mediating the effect of insulin therapy on DR risk. However, because of the cross-validation strategy, we will validate the present finding in an independent cohort in the near future.
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